A Phase 2 interventional study of BI 764198 and Placebo in COVID-19, sponsored by Boehringer Ingelheim. Terminated at 25 sites in 6 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-04-11.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 560th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 767th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 133 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 4 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is open to adults with COVID-19 infection who are in hospital and receive oxygen. Participants need to be 50 years of age or older and need to be at risk of further worsening of their condition.
The purpose of the study is to find out whether a medicine called BI 764198 helps people with COVID-19 infection and breathing problems. BI 764198 may prevent cell death and swelling of the lung tissue and therefore help patients with COVID-19 infection.
Participants are put into 2 groups by chance. One group of participants gets BI 764198 capsules and the other group gets placebo capsules. The placebo capsules look exactly like the BI 764198 capsules but do not contain any medicine. Participants take 1 capsule per day.
Participants are in the study for about a month. At study end, doctors compare the 2 groups for the number of patients that are alive and do not need mechanical breathing support. During the study, the doctors collect information on any health problems of the participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of the following cardiac conditions:
History of long QT features on electrocardiogram (ECG) or history of familial long QT
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BI 764198
Drug: Placebo
BI 764198
Placebo
Percentage of Patients Alive and Free of Mechanical Ventilation
Percentage of patients alive and free of mechanical ventilation at Day 29 is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).
Time frame: At Day 29
Percentage of Patients Alive and Discharged Free of Oxygen Use
Percentage of patients alive and discharged free of oxygen use is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).
Time frame: At Day 29
Percentage of Patients With Occurrence of Any Component of Composite: In-hospital Mortality or Intensive Care Unit (ICU) Admission or Mechanical Ventilation
Percentage of patients with occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation is presented. Efficacy endpoint meets when a patient has occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation at Day 29. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).
Time frame: At Day 29
Time to Clinical Improvement of at Least 2 Points (From Randomisation) on the World Health Organization Clinical Progression Scale, Discharge From the Hospital, or Considered Fit for Discharge
Meets when improvement of at least 2 points on World Health Organization (WHO) Clinical Progression Scale (CPS), discharge from hospital, fit for discharge (score 0, 1, 2, 3 on CPS), whichever comes first. WHO CPS: 0. Uninfected; no viral RNA detected; 1. Asymptomatic; viral RNA detected; 2. Symptomatic; independent; 3. Symptomatic; assistance needed; 4. Hospitalised; no oxygen therapy; 5. Hospitalised; oxygen by mask or nasal prongs; 6. Hospitalised; oxygen by non-invasive ventilation or high flow; 7. Intubation + mechanical ventilation, partial pressure of oxygen/fraction of inspired oxygen (pO2/FiO2) ≥150 or oxygen saturation/FiO2 (SpO2/FiO2) ≥200; 8. Mechanical ventilation pO2/FiO2 \<150 (SpO2/FiO2 \<200) or vasopressors; 9. Mechanical ventilation pO2/FiO2 \<150 + vasopressors, dialysis, extracorporeal membrane oxygenation (ECMO); 10. Death Only patients with event were analysed. One patient had no creatinine at baseline value, therefore excluded from statistical analysis (N=128).
Time frame: Up to Day 29
Number of Ventilator Free Days
Number of ventilator free days by Day 29 is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).
Time frame: Up to Day 29
Percentage of Mortality at Day 15, 29, 60 and 90
Percentage of mortality is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).
Time frame: At Day 15, 29, 60 and 90
This randomised, placebo-controlled, double-blind, proof-of-concept exploratory trial was to evaluate the efficacy and safety of BI 764198, an inhibitor of the transient receptor potential subtype C6 (TRPC6), compared to placebo in reducing risk or severity of acute respiratory distress syndrome (ARDS) in patients hospitalised for coronavirus disease appeared in 2019 (COVID-19).
| Milestone | BI 764198 Treatment Group | Placebo |
|---|---|---|
| Started | 67 | 66 |
| Treated | 65 | 64 |
| Completed | 47 | 47 |
| Not completed | 20 | 19 |
| Withdrew: Adverse event | 5 | 5 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Not treated | 2 | 2 |
| Withdrew: Due to sponsor decision | 9 | 7 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Transfer to healthcare | 1 | 0 |
Percentage of patients alive and free of mechanical ventilation at Day 29 is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).
| Percentage of patients | BI 764198 Treatment Group | Placebo |
|---|---|---|
| Percentage of Patients Alive and Free of Mechanical Ventilation | 83.1 | 87.5 |
Percentage of patients alive and discharged free of oxygen use is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).
| Percentage of patients | BI 764198 Treatment Group | Placebo |
|---|---|---|
| Percentage of Patients Alive and Discharged Free of Oxygen Use | 75.4 | 82.8 |
Percentage of patients with occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation is presented. Efficacy endpoint meets when a patient has occurrence of any component of composite: In-hospital mortality or intensive care unit (ICU) admission or mechanical ventilation at Day 29. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).
| Percentage of patients | BI 764198 Treatment Group | Placebo |
|---|---|---|
| Percentage of Patients With Occurrence of Any Component of Composite: In-hospital Mortality or Intensive Care Unit (ICU) Admission or Mechanical Ventilation | 26.2 | 23.4 |
Meets when improvement of at least 2 points on World Health Organization (WHO) Clinical Progression Scale (CPS), discharge from hospital, fit for discharge (score 0, 1, 2, 3 on CPS), whichever comes first. WHO CPS: 0. Uninfected; no viral RNA detected; 1. Asymptomatic; viral RNA detected; 2. Symptomatic; independent; 3. Symptomatic; assistance needed; 4. Hospitalised; no oxygen therapy; 5. Hospitalised; oxygen by mask or nasal prongs; 6. Hospitalised; oxygen by non-invasive ventilation or high flow; 7. Intubation + mechanical ventilation, partial pressure of oxygen/fraction of inspired oxygen (pO2/FiO2) ≥150 or oxygen saturation/FiO2 (SpO2/FiO2) ≥200; 8. Mechanical ventilation pO2/FiO2 \<150 (SpO2/FiO2 \<200) or vasopressors; 9. Mechanical ventilation pO2/FiO2 \<150 + vasopressors, dialysis, extracorporeal membrane oxygenation (ECMO); 10. Death Only patients with event were analysed. One patient had no creatinine at baseline value, therefore excluded from statistical analysis (N=128).
| Days | BI 764198 Treatment Group | Placebo |
|---|---|---|
| Time to Clinical Improvement of at Least 2 Points (From Randomisation) on the World Health Organization Clinical Progression Scale, Discharge From the Hospital, or Considered Fit for Discharge | 9 (6 to 24) | 7 (5 to 10) |
Number of ventilator free days by Day 29 is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).
| Days | BI 764198 Treatment Group | Placebo |
|---|---|---|
| Number of Ventilator Free Days | 24.12 ± 8.81 | 25.08 ± 7.85 |
Percentage of mortality is presented. One patient had no creatinine at baseline value and was therefore excluded from the statistical analysis (N=128).
| Percentage of patients | BI 764198 Treatment Group | Placebo |
|---|---|---|
| Day 15 | 6.2 | 1.6 |
| Day 29 | 12.3 | 7.8 |
| Day 60 | 15.4 | 7.8 |
| Day 90 | 16.9 | 7.8 |
Collected over From first administration of the study drug to end of study, 90 days in total.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BI 764198 Treatment Group | 11/65 (16.9%) | 19/65 (29.2%) | 10/65 (15.4%) |
| Placebo | 5/64 (7.8%) | 17/64 (26.6%) | 12/64 (18.8%) |
| Event | BI 764198 Treatment Group | Placebo |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 4/65 | 5/64 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 4/65 | 5/64 |
| COVID-19 pneumoniaInfections and infestations | 4/65 | 2/64 |
| Septic shockInfections and infestations | 2/65 | 3/64 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 2/65 | 3/64 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/65 | 2/64 |
| Cardiac failure congestiveCardiac disorders | 0/65 | 2/64 |
| COVID-19Infections and infestations | 1/65 | 2/64 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/65 | 2/64 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/65 | 0/64 |
| Event | BI 764198 Treatment Group | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 4/65 | 6/64 |
| HyperkalaemiaMetabolism and nutrition disorders | 2/65 | 6/64 |
| HypotensionVascular disorders | 4/65 | 5/64 |
| Electrocardiogram QT prolongedInvestigations | 3/65 | 4/64 |
| TachycardiaCardiac disorders | 0/65 | 4/64 |
Full Analysis Set (FAS): FAS included all patients (pts) in randomized set (RS) who received at least 1 dose of trial drug, comprised 129 pts (85.4%). Of all pts randomised, number (%) of pts not treated was similar in BI 764198 (2/67 pts \[3.0%\]) and placebo group (2/66 pts \[3.0%\]). The 4 pts excluded from FAS discontinued trial before receiving treatment for following reasons: pt's withdrawal (n=2), meeting an exclusion criterion (n=1), and clinical worsening (n=1).
| Age, Continuous(Years) | BI 764198 Treatment Group | Placebo | Total |
|---|---|---|---|
| Mean | 63.8 ± 8.3 | 63.6 ± 7.9 | 63.7 ± 8.1 |
| Sex: Female, Male(Participants) | BI 764198 Treatment Group | Placebo | Total |
|---|---|---|---|
| Female | 24 | 25 | 49 |
| Male | 41 | 39 | 80 |
| Ethnicity (NIH/OMB)(Participants) | BI 764198 Treatment Group | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 39 | 35 | 74 |
| Not Hispanic or Latino | 26 | 29 | 55 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BI 764198 Treatment Group | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 5 | 7 | 12 |
| Asian | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 3 | 3 | 6 |
| White | 53 | 47 | 100 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Nov 2020 to primary completion in Mar 2021, 4 months.
Results were first posted in Apr 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BI-764198